Despite significant advances in microsurgical treatment of glaucoma, glaucomatous optic neuropathy (GON) continues to progress in more than half of patients. Lt is proved that the main pathogenetic factors of its development after normalization of LOP are hemomicrocirculation disorders and the associated violation of transcapillary exchange in the optic nerve. This causes damage to the axons of the ganglion cells, leading to their apoptosis and death. According to leading glaucomatologists, the pathogenetically targeted treatment is the use of medications with neuroprotective and antioxidant effects. In clinical medicine, in particular, in the treatment of ischemic brain conditions, the drug of complex action, Gliatilin, is widely used. Gliatilin - choline alfoscerate is a central cholinomimetic with a primary effect on the central nervous system.